Longevity & Aging · Metabolic & Cardiometabolic
exogenous insulin therapy for T2D worsens long-term T2D outcomes
In plain terms: Does taking insulin for type 2 diabetes make the disease worse over time?
Part of: • Insulin & Metabolic Aging
No — the one large randomized trial (ORIGIN) found insulin cardiovascular-neutral, and long-term follow-up (UKPDS) shows a durable benefit, not harm. Observational 'insulin causes harm' signals are confounded (sicker patients get insulin). Important: this is not a reason to stop or reduce prescribed insulin — for many people, especially with type 1 diabetes, insulin is life-saving, and any change should only be made with your physician.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
>
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR 2024 · Lancet | RCT | contradicts | high | 24-yr UKPDS monitoring found enduring/emerging glycemic legacy benefit from early intensive control (including insulin arm), with no waning, arguing against long-term harm from the insulin-containing strategy. |
| Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL 2013 · J Clin Endocrinol Metab | observational | supports | low | Retrospective cohort linked insulin vs other antihyperglycemic therapies to higher mortality and diabetes-related outcomes, raising safety concerns but unable to exclude that sicker patients receive insulin. |
| Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 2008 · N Engl J Med | RCT | contradicts | high | 10-yr post-trial follow-up of intensive glucose control (sulfonylurea/insulin) showed sustained reduction in microvascular disease and emergent reductions in myocardial infarction and all-cause mortality (legacy effect), opposite to a worsening-progression claim. |
| Abid MA, Abid MH, Afzal MD 2026 · Ann Med Surg | observational | tested-null | low | Commentary on insulin icodec, not evidence: summarises approval-trial data; 'The most commonly reported adverse effects include hypoglycemia, injection site reactions, and weight gain.' No long-term T2D outcome data. Review — zero weight. |
| Buse JB 2015 · Trans Am Clin Climatol Assoc | RCT | mixed | moderate | Narrative review by an ACCORD investigator, no new data: 'intensive management targeting normal levels of glycemia was associated with increased mortality and the ACCORD trial was terminated early in 2008'; 'Post hoc analyses ... are the subject of this review.' Intensive strategy, not insulin per se. Zero weight - ACCORD is the evidence. |
| Abdella NA 2002 · Kuwait Med J | mechanism | contradicts | low | Reviews the hyperinsulinemia-is-atherogenic hypothesis and concludes high insulin is a marker of insulin resistance, not a proven direct cause of atherosclerosis; benefit of glycemic control outweighs the theoretical hyperinsulinemia concern. |
| Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ 2015 · Diabetes Obes Metab | observational | supports | low | In insulin-monotherapy T2D, higher insulin dose was associated with increased all-cause mortality, MACE and cancer — but observationally, with strong confounding by indication. |
| Yang B, Ha J, Sherman AS 2026 · Am J Physiol Endocrinol Metab | mechanism | contradicts | moderate | Mathematical modeling of longitudinal Southwest Native American data found hyperinsulinemia reflects compensation for insulin resistance rather than a primary defect; high insulin secretion alone does not initiate diabetes unless |
| Currie CJ, Holden SE, Jenkins-Jones S, Morgan CL, Voss B, Rajpathak SN, Alemayehu B, Peters JR, Engel SS 2018 · Diabetes Obes Metab | observational | mixed | low | Association between achieved HbA1c and survival differed by regimen's hypoglycemia risk (U-shaped, worse at low HbA1c on insulin/sulfonylurea), implicating hypoglycemia/glucose level rather than insulin causing progression. |
| Lin YC, Chen CW, Huang LY, Chen BL, Shao YJ, Huang CY 2025 · Sci Rep | observational | tested-null | moderate | Confirmed U-shaped HbA1c-mortality/MACE relationship; both high and low glucose raise risk, with lowest-risk HbA1c about 6.7-7.2%, indicating danger is dysglycemia/overtreatment, not insulin therapy itself. |
| Hanefeld M, Monnier L, Schnell O, Owens D 2016 · Diabetes Ther | observational | contradicts | low | Sanofi-funded narrative review (JATS review-article), re-describing ORIGIN: 'In the cardiovascular outcome trial, outcome reduction with an initial glargine intervention (ORIGIN), a neutral effect on cardiovascular disease was observed in the population comprising prediabetes and T2DM. Worsening of glycemic control was prevented over the 6.7 year treatment period'. Review — zero weight; ORIGIN should vote via its own primary report. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.